Literature DB >> 26037285

Physicochemical characterisation of rVIII-SingleChain, a novel recombinant single-chain factor VIII.

Stefan Schmidbauer1, Reinhild Witzel2, Lars Robbel2, Petra Sebastian2, Nicolas Grammel3, Hubert J Metzner2, Stefan Schulte2.   

Abstract

rVIII-SingleChain is a novel recombinant single-chain factor VIII (FVIII) construct, comprising covalently bonded heavy and light chains. Post-translational modifications of FVIII affect physicochemical parameters, including hydrophobicity and charge. The most relevant post-translational modifications of FVIII products are N-glycosylation of asparagine residues and tyrosine sulphations. Here, the physicochemical properties, thrombin cleavage products and post-translational modifications of rVIII-SingleChain were investigated and compared against commercially available recombinant FVIII (rFVIII) products with a predominant two-chain structure (B-domain deleted rFVIII and full-length rFVIII). rVIII-SingleChain was expressed in Chinese hamster ovary (CHO) cells and purified by chromatographic methods. Physicochemical properties of rVIII-SingleChain or thrombin-derived cleavage products were assessed using size-exclusion chromatography, reversed-phase chromatography and sodium dodecyl sulphate polyacrylamide gel electrophoresis. Analysis of the respective carbohydrate structures was performed after release of N-glycans by PNGase F followed by fluorescence labelling and high-performance liquid chromatography. Proteolysis by trypsin generated the corresponding peptides, which were analysed for sulphated tyrosines by liquid chromatography-electrospray ionisation time of flight-mass spectrometry. rVIII-SingleChain was shown to be of high purity and homogeneity, and presented a well-defined single-chain molecule with predominant β-sheet conformation. The coagulation-relevant thrombin-activation products of rVIII-SingleChain were comparable with those obtained by activation of commercially available rFVIII products. rVIII-SingleChain post-translational modifications were similar to other CHO cell-derived rFVIII products for N-glycopattern and tyrosine sulphation. In conclusion, rVIII-SingleChain is of high homogeneity and purity, and provides an expected cleavage pattern on activation, setting the basis for optimal efficacy in the patient.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Factor VIII; Physicochemical; Recombinant; rVIII-SingleChain

Mesh:

Substances:

Year:  2015        PMID: 26037285     DOI: 10.1016/j.thromres.2015.05.005

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  10 in total

1.  BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice.

Authors:  Ekta Seth Chhabra; Tongyao Liu; John Kulman; Susannah Patarroyo-White; Buyue Yang; Qi Lu; Douglas Drager; Nancy Moore; Jiayun Liu; Amy M Holthaus; Jurg M Sommer; Ayman Ismail; Deana Rabinovich; Zhan Liu; Arjan van der Flier; Allison Goodman; Chris Furcht; Mark Tie; Tyler Carlage; Randy Mauldin; Terrence M Dobrowsky; Zhiqian Liu; Oblaise Mercury; Lily Zhu; Baisong Mei; Volker Schellenberger; Haiyan Jiang; Glenn F Pierce; Joe Salas; Robert Peters
Journal:  Blood       Date:  2020-04-23       Impact factor: 22.113

Review 2.  Extended Half-Life Factor VIII and Factor IX Preparations.

Authors:  Lukas Graf
Journal:  Transfus Med Hemother       Date:  2018-03-21       Impact factor: 3.747

Review 3.  Novel therapies and current clinical progress in hemophilia A.

Authors:  Pauline Balkaransingh; Guy Young
Journal:  Ther Adv Hematol       Date:  2017-12-28

Review 4.  Current and emerging factor VIII replacement products for hemophilia A.

Authors:  Lorraine A Cafuir; Christine L Kempton
Journal:  Ther Adv Hematol       Date:  2017-08-26

Review 5.  Pharmacokinetic-based prediction of real-life dosing of extended half-life clotting factor concentrates on hemophilia.

Authors:  Massimo Morfini; Stefano Gherardini
Journal:  Ther Adv Hematol       Date:  2018-06-05

6.  Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A.

Authors:  G N Nguyen; L A George; J I Siner; R J Davidson; C B Zander; X L Zheng; V R Arruda; R M Camire; D E Sabatino
Journal:  J Thromb Haemost       Date:  2016-11-25       Impact factor: 5.824

Review 7.  Outcome of Clinical Trials with New Extended Half-Life FVIII/IX Concentrates.

Authors:  Maria Elisa Mancuso; Elena Santagostino
Journal:  J Clin Med       Date:  2017-03-28       Impact factor: 4.241

Review 8.  Immune Responses to Plasma-Derived Versus Recombinant FVIII Products.

Authors:  Flora Peyvandi; Syna Miri; Isabella Garagiola
Journal:  Front Immunol       Date:  2021-01-22       Impact factor: 7.561

Review 9.  Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?

Authors:  Kenneth Lieuw
Journal:  J Blood Med       Date:  2017-06-15

Review 10.  An Update on Laboratory Diagnostics in Haemophilia A and B.

Authors:  Jens Müller; Wolfgang Miesbach; Florian Prüller; Thomas Siegemund; Ute Scholz; Ulrich J Sachs
Journal:  Hamostaseologie       Date:  2022-02-01       Impact factor: 2.145

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.